Impact of oral fidaxomicin administration on the intestinal microbiota and susceptibility to clostridium difficile colonization in mice

Antimicrobial Agents and Chemotherapy

Volumn 62, Issue 5, 2018, Pages

  Ajami, N J ^a,b   Cope, J L ^a,b   Wong, M C ^b   Petrosino, J F ^a,b   Chesnel, L ^c  

^a Diversigen Inc   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Clostridium difficile; Diarrhea; Fidaxomicin; Recurrences; Vancomycin

Indexed keywords

FIDAXOMICIN; RNA 16S; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANIMAL EXPERIMENT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL SPORE; BIODIVERSITY; CLOSTRIDIALES; CLOSTRIDIUM DIFFICILE INFECTION; DRUG EXPOSURE; ENTEROBACTERIALES; ENTEROCOCCUS; FECES; FEMALE; GENE SEQUENCE; HOSPITAL INFECTION; INTESTINE FLORA; MICROBIAL COMMUNITY; MOUSE; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PRIORITY JOURNAL; ANIMAL; C57BL MOUSE; CLOSTRIDIUM INFECTION; CROSS INFECTION; DISEASE MODEL; DRUG EFFECT; GENETICS; MICROBIOLOGY;

ANIMALS; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; DISEASE MODELS, ANIMAL; FECES; FEMALE; FIDAXOMICIN; GASTROINTESTINAL MICROBIOME; MICE; MICE, INBRED C57BL; RNA, RIBOSOMAL, 16S; VANCOMYCIN;

EID: 85046009441     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02112-17     Document Type: Article

References (41)

1. Reveles KR, Lee GC, Boyd NK, Frei CR. 2014. The rise in Clostridium difficile infection incidence among hospitalized adults in the United States: 2001–2010. Am J Infect Control 42:1028–1032. https://doi.org/10.1016/j.ajic.2014.06.011.
2. Lessa FC, Gould CV, McDonald LC. 2012. Current status of Clostridium difficile infection epidemiology. Clin Infect Dis 55(Suppl 2):S65–S70. https://doi.org/10.1093/cid/cis319.
3. Khanna S, Pardi DS. 2012. Clostridium difficile infection: new insights into management. Mayo Clin Proc 87:1106–1117. https://doi.org/10.1016/j.mayocp.2012.07.016.
4. Khanna S, Pardi DS. 2016. Clinical implications of antibiotic impact on gastrointestinal microbiota and Clostridium difficile infection. Expert Rev Gastroenterol Hepatol 10:1– 8. https://doi.org/10.1586/17474124.2016.1120157.
5. Ofosu A. 2016. Clostridium difficile infection: a review of current and emerging therapies. Ann Gastroenterol 29:147–154. https://doi.org/10.20524/aog.2016.0006.
6. Slimings C, Riley TV. 2014. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother 69:881–891. https://doi.org/10.1093/jac/dkt477.
7. Brown KA, Khanafer N, Daneman N, Fisman DN. 2013. Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection. Antimicrob Agents Chemother 57:2326–2332. https://doi.org/10.1128/AAC.02176-12.
8. Deshpande A, Pasupuleti V, Thota P, Pant C, Rolston DD, Sferra TJ, Hernandez AV, Donskey CJ. 2013. Community-associated Clostridium difficile infection and antibiotics: a meta-analysis. J Antimicrob Chemother 68:1951–1961. https://doi.org/10.1093/jac/dkt129.
9. Ley RE, Peterson DA, Gordon JI. 2006. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell 124:837–848. https://doi.org/10.1016/j.cell.2006.02.017.
10. Maroo S, Lamont JT. 2006. Recurrent Clostridium difficile. Gastroenter-ology 130:1311–1316. https://doi.org/10.1053/j.gastro.2006.02.044.
11. Pépin J, Saheb N, Coulombe MA, Alary ME, Corriveau MP, Authier S, Leblanc M, Rivard G, Bettez M, Primeau V, Nguyen M, Jacob CE, Lanthier L. 2005. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 41:1254–1260. https://doi.org/10.1086/496986.
12. Ma GK, Brensinger CM, Wu Q, Lewis JD. 2017. Increasing incidence of multiply recurrent Clostridium difficile infection in the United States: a cohort study. Ann Intern Med 167:152–158. https://doi.org/10.7326/M16-2733.
13. Saini SD, Waljee AK. 2017. Fool me thrice: the evolving story of multiply recurrent Clostridium difficile infection. Ann Intern Med 167:202–203. https://doi.org/10.7326/M17-1565.
14. Kelly CP, LaMont JT. 2008. Clostridium difficile–more difficult than ever. N Engl J Med 359:1932–1940. https://doi.org/10.1056/NEJMra0707500.
15. Khanna S, Pardi DS, Aronson SL, Kammer PP, Orenstein R, St Sauver JL, Harmsen WS, Zinsmeister AR. 2012. The epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am J Gastroenterol 107:89–95. https://doi.org/10.1038/ajg.2011.398.
16. McFarland LV, Elmer GW, Surawicz CM. 2002. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 97:1769–1775. https://doi.org/10.1111/j.1572-0241.2002.05839.x.
17. Sheitoyan-Pesant C, Abou Chakra CN, Pepin J, Marcil-Héguy A, Nault V, Valiquette L. 2016. Clinical and healthcare burden of multiple recurrences of Clostridium difficile infection. Clin Infect Dis 62:574–580. https://doi.org/10.1093/cid/civ958.
18. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. 2006. Microbial ecology: human gut microbes associated with obesity. Nature 444:1022–1023. https://doi.org/10.1038/4441022a.
19. Louie TJ, Cannon K, Byrne B, Emery J, Ward L, Eyben M, Krulicki W. 2012. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis 55(Suppl 2): S132–S142. https://doi.org/10.1093/cid/cis338.
20. Deshpande A, Hurless K, Cadnum JL, Chesnel L, Gao L, Chan L, Kundrapu S, Polinkovsky A, Donskey CJ. 2016. Effect of fidaxomicin versus vancomycin on susceptibility to intestinal colonization with vancomycin-resistant enterococci and Klebsiella pneumoniae in mice. Antimicrob Agents Chemother 60:3988–3993. https://doi.org/10.1128/AAC.02590-15.
21. Chang JY, Antonopoulos DA, Kalra A, Tonelli A, Khalife WT, Schmidt TM, Young VB. 2008. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis 197:435–438. https://doi.org/10.1086/525047.
22. Leffler DA, Lamont JT. 2015. Clostridium difficile infection. N Engl J Med 373:287–288. https://doi.org/10.1056/NEJMc1506004.
23. Neu HC, Gootz TD. 1996. Antimicrobial Chemotherapy. In Baron S (ed), Medical microbiology, 4th ed. University of Texas Medical Branch at Galveston, Galveston, TX.
24. Brook I, Wexler HM, Goldstein EJ. 2013. Antianaerobic antimicrobials: spectrum and susceptibility testing. Clin Microbiol Rev 26:526–546. https://doi.org/10.1128/CMR.00086-12.
25. Mullane KM, Gorbach S. 2011. Fidaxomicin: first-in-class macrocyclic antibiotic. Expert Rev Anti Infect Ther 9:767–777. https://doi.org/10.1586/eri.11.53.
26. Tannock GW, Munro K, Taylor C, Lawley B, Young W, Byrne B, Emery J, Louie T. 2010. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology 156:3354 –3359. https://doi.org/10.1099/mic.0.042010-0.
27. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK, PT-80-003 Clinical Study Group. 2011. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 364: 422–431. https://doi.org/10.1056/NEJMoa0910812.
28. Nerandzic MM, Mullane K, Miller MA, Babakhani F, Donskey CJ. 2012. Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection. Clin Infect Dis 55(Suppl 2):S121–S126. https://doi.org/10.1093/cid/cis440.
29. Donskey CJ, Chowdhry TK, Hecker MT, Hoyen CK, Hanrahan JA, Hujer AM, Hutton-Thomas RA, Whalen CC, Bonomo RA, Rice LB. 2000. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N Engl J Med 343:1925–1932. https://doi.org/10.1056/NEJM200012283432604.
30. Abujamel T, Cadnum JL, Jury LA, Sunkesula VC, Kundrapu S, Jump RL, Stintzi AC, Donskey CJ. 2013. Defining the vulnerable period for reestablishment of Clostridium difficile colonization after treatment of C. difficile infection with oral vancomycin or metronidazole. PLoS One 8:e76269. https://doi.org/10.1371/journal.pone.0076269.
31. Chilton CH, Crowther GS, Ashwin H, Longshaw CM, Wilcox MH. 2016. Association of fidaxomicin with C. difficile spores: effects of persistence on subsequent spore recovery, outgrowth and toxin production. PLoS One 11:e0161200. https://doi.org/10.1371/journal.pone.0161200.
32. Buffie CG, Bucci V, Stein RR, McKenney PT, Ling L, Gobourne A, No D, Liu H, Kinnebrew M, Viale A, Littmann E, van den Brink MR, Jenq RR, Taur Y, Sander C, Cross JR, Toussaint NC, Xavier JB, Pamer EG. 2015. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 517:205–208. https://doi.org/10.1038/nature13828.
33. Lewis BB, Buffie CG, Carter RA, Leiner I, Toussaint NC, Miller LC, Gobourne A, Ling L, Pamer EG. 2015. Loss of microbiota-mediated colonization resistance to Clostridium difficile infection with oral vancomycin compared with metronidazole. J Infect Dis 212:1656–1665. https://doi.org/10.1093/infdis/jiv256.
34. Edgar RC. 2013. UPARSE: highly accurate OTU sequences from microbial amplicon reads. Nat Methods 10:996–998. https://doi.org/10.1038/nmeth.2604.
35. Quast C, Pruesse E, Yilmaz P, Gerken J, Schweer T, Yarza P, Peplies J, Glockner FO. 2013. The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. Nucleic Acids Res 41: D590–D596. https://doi.org/10.1093/nar/gks1219.
36. Edgar RC. 2010. Search and clustering orders of magnitude faster than BLAST. Bioinformatics 26:2460–2461. https://doi.org/10.1093/bioinformatics/btq461.
37. Core Team R. 2014. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.
38. Paradis E, Claude J, Strimmer K. 2004. APE: Analyses of Phylogenetics and Evolution in R language. Bioinformatics 20:289–290. https://doi.org/10.1093/bioinformatics/btg412.
39. Kruskal WH, Wallis WA. 1952. Use of ranks in one-criterion variance analysis. J Am Stat Assoc 47:583–621. https://doi.org/10.1080/01621459.1952.10483441.
40. Dwass M. 1957. Modified randomization tests for nonparametric hypotheses. Ann Math Stat 28:181–187. https://doi.org/10.1214/aoms/1177707045.
41. Benjamini YHY. 1995. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc 57:289–300.